Auxilium Pharmaceuticals (AUXL) Stock Price, News & Analysis

Company Overview

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company that focuses on developing and marketing products to predominantly specialist audiences. Its core therapeutic focus continues to be in the area of urology, with an anchor position in men's healthcare. The company's products include Testim (testosterone gel) and testosterone gel are indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; TESTOPEL offers men an option that provides a long-acting androgenic effect; Striant (testosterone buccal system) CIII is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction; among others.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 1.32 million shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AUXL Stock Analysis - Frequently Asked Questions

How were Auxilium Pharmaceuticals' earnings last quarter?

Auxilium Pharmaceuticals Inc (NASDAQ:AUXL) released its earnings results on Thursday, October, 30th. The biopharmaceutical company reported $0.27 earnings per share for the quarter, topping analysts' consensus estimates of ($0.03) by $0.30. The firm's revenue was up 1.4% on a year-over-year basis.

What other stocks do shareholders of Auxilium Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Auxilium Pharmaceuticals investors own include Royalty Pharma (RPRX), Yelp (YELP), AEGR (AEGR), Arctos NorthStar Acquisition (ANAC), MannKind (MNKD), Netflix (NFLX) and Tesla (TSLA).

Company Calendar

• Last Earnings: 10/30/2014
• Today: 5/06/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:AUXL
• CIK: 1182129
• Web: www.auxilium.com
• Phone: +1-484-3215900
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A